CN113543847A - 微小rna的表达增强剂和微小rna表达增强用饮食品 - Google Patents
微小rna的表达增强剂和微小rna表达增强用饮食品 Download PDFInfo
- Publication number
- CN113543847A CN113543847A CN202080018663.XA CN202080018663A CN113543847A CN 113543847 A CN113543847 A CN 113543847A CN 202080018663 A CN202080018663 A CN 202080018663A CN 113543847 A CN113543847 A CN 113543847A
- Authority
- CN
- China
- Prior art keywords
- mir
- microrna
- expression
- pterostilbene
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 98
- 239000002679 microRNA Substances 0.000 title claims abstract description 57
- 108700011259 MicroRNAs Proteins 0.000 title claims description 55
- 230000002708 enhancing effect Effects 0.000 title claims description 27
- 235000013305 food Nutrition 0.000 title claims description 18
- 239000003795 chemical substances by application Substances 0.000 title description 7
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims abstract description 60
- 239000003623 enhancer Substances 0.000 claims abstract description 57
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims abstract description 56
- 108091070501 miRNA Proteins 0.000 claims abstract description 36
- 108091028066 Mir-126 Proteins 0.000 claims abstract description 20
- 108091091807 let-7a stem-loop Proteins 0.000 claims abstract description 20
- 108091057746 let-7a-4 stem-loop Proteins 0.000 claims abstract description 20
- 108091028376 let-7a-5 stem-loop Proteins 0.000 claims abstract description 20
- 108091024393 let-7a-6 stem-loop Proteins 0.000 claims abstract description 20
- 108091091174 let-7a-7 stem-loop Proteins 0.000 claims abstract description 20
- 108091027943 miR-16 stem-loop Proteins 0.000 claims abstract description 20
- 108091039097 miR-193b stem-loop Proteins 0.000 claims abstract description 20
- 108091029119 miR-34a stem-loop Proteins 0.000 claims abstract description 20
- 108091058688 miR-141 stem-loop Proteins 0.000 claims description 19
- 108091074450 miR-200c stem-loop Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229920002477 rna polymer Polymers 0.000 claims 1
- 239000003921 oil Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 239000002285 corn oil Substances 0.000 description 6
- 235000005687 corn oil Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 241000254173 Coleoptera Species 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000003983 inhalation anesthetic agent Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108091027977 Mir-200 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 238000004388 gamma ray sterilization Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 238000003253 miRNA assay Methods 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
Abstract
本发明涉及一种表达增强剂,其为含有紫檀芪的微小RNA的表达增强剂,微小RNA为选自由miR‑34a、miR‑16、miR‑126、miR‑193b和let‑7a组成的组中的至少1种。
Description
技术领域
本发明涉及微小RNA的表达增强剂和微小RNA表达增强用饮食品。
背景技术
微小RNA是碱基对长度约为22个碱基的RNA。已知作为芪类衍生物的白藜芦醇和紫檀芪会促进或抑制这样的微小RNA中的特定的微小RNA的表达(非专利文献1和2)。
现有技术文献
非专利文献
非专利文献1:Scientific Reports,2,314,2012
非专利文献2:Oncotarget,2015年,第6卷,29号,pp.27214-27226
发明内容
发明要解决的问题
近些年,关于miR-200c、miR-141、miR-34a、miR-16、miR-126、miR-193b和let-7a这样的微小RNA,已经明确了表达量的异常与癌症、骨质疏松症、心肌梗塞、脑部疾病、循环系统疾病、痴呆、牙周病等疾病的发生相关,能够控制(增强)上述微小RNA的表达量的化合物作为各种疾病的治疗剂和/或预防剂等是有用的。
因此,本发明的目的在于提供微小RNA的新的表达增强剂。
用于解决问题的方案
本发明例如涉及以下的各发明。
(1)一种表达增强剂,其为含有紫檀芪(Pterostilbene)的微小RNA的表达增强剂,微小RNA为选自由miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
(2)根据(1)所述的表达增强剂,其用于经口给予。
(3)一种表达增强剂,其为含有紫檀芪的经口给予用的微小RNA的表达增强剂,微小RNA为选自由miR-200c和miR-141组成的组中的至少1种。
(4)一种饮食品,其为包含紫檀芪的微小RNA表达增强用饮食品,微小RNA为选自由miR-200c、miR-141、miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
(5)一种增强微小RNA的表达的方法,其包括向需要其的对象给予紫檀芪的步骤,微小RNA为选自由miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
(6)一种增强微小RNA的表达的方法,其包括向需要其的对象经口给予紫檀芪的步骤,微小RNA为选自由miR-200c和miR-141组成的组中的至少1种。
(7)一种紫檀芪的应用,用于制造微小RNA的表达增强剂,其中,微小RNA为选自由miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
(8)一种紫檀芪的应用,用于制造微小RNA的经口给予用表达增强剂,其中,微小RNA为选自由miR-200c和miR-141组成的组中的至少1种。
(9)一种紫檀芪,其用于增强微小RNA的表达,微小RNA为选自由miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
(10)一种紫檀芪,其用于通过经口给予而增强微小RNA的表达,微小RNA为选自由miR-200c和miR-141组成的组中的至少1种。
发明的效果
根据本发明,提供微小RNA的新的表达增强剂。
附图说明
图1的(A)~(D)是分别示出miR-200c、miR-141、miR-34a和miR-16的表达量的测定结果的图。
图2的(A)~(C)是分别示出miR-126、miR-193b和let-7a的表达量的测定结果的图。
具体实施方式
以下,对用于实施本发明的方式进行详细地说明。但是,本发明不限定于以下的实施方式。
<本发明的特征>
(微小RNA的表达增强剂)
本发明具有如下特征:提供一种表达增强剂,所述表达增强剂为含有紫檀芪的微小RNA的表达增强剂,微小RNA为选自由miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
(经口给予用的微小RNA的表达增强剂)
本发明具有如下特征:提供一种表达增强剂,所述表达增强剂为含有紫檀芪的经口给予用的微小RNA的表达增强剂,微小RNA为选自由miR-200c和miR-141组成的组中的至少1种。
(饮食品)
本发明还具有如下特征:提供一种饮食品,所述饮食品为包含紫檀芪的微小RNA表达增强用饮食品,微小RNA为选自由miR-200c、miR-141、miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
<微小RNA的表达增强剂>
“微小RNA的表达增强剂”可以使微小RNA从微小RNA的表达量已降低的状态增加至与健康的人(healthy person)同样的表达量,也可以将微小RNA的表达量维持在与健康的人同样的表达量。即,微小RNA的表达增强剂也可以称为微小RNA的表达调节剂、表达控制剂或表达促进剂。
<微小RNA>
本实施方式的表达增强剂增强miR-200c、miR-141、miR-34a、miR-16、miR-126、miR-193b和let-7a的表达。因此,本实施方式的表达增强剂可以用作上述微小RNA中的1种或2种以上的表达增强剂。
<微小RNA的表达增强剂的用途>
上述的微小RNA的表达增强剂可以适宜地用作癌症、骨质疏松症、心肌梗塞、脑部疾病、循环系统疾病、痴呆、牙周病等疾病的治疗剂和/或预防剂。
<各微小RNA的序列>
上述的微小RNA是成熟的单链的微小RNA,分别具有以下所示的序列。
(1)miR-200c:UAAUACUGCCGGGUAAUGAUGGA(序列号1)
(2)miR-141:UAACACUGUCUGGUAAAGAUGG(序列号2)
(3)miR-34a:UGGCAGUGUCUUAGCUGGUUGU(序列号3)
(4)miR-16:UAGCAGCACGUAAAUAUUGGCG(序列号4)
(5)miR-126:UCGUACCGUGAGUAAUAAUGCG(序列号5)
(6)miR-193b:AACUGGCCCUCAAAGUCCCGCU(序列号6)
(7)let-7a:UGAGGUAGUAGGUUGUAUAGUU(序列号7)
<紫檀芪>
紫檀芪(Pterostilbene)是由下述式(1)表示的化合物。
<紫檀芪的含量>
本实施方式的表达增强剂中,紫檀芪的含量以表达增强剂总量为基准计可以为0.01质量%以上或0.10质量%以上,或者10质量%以下或5质量%以下。
<紫檀芪的获得方法>
本实施方式中,紫檀芪可以使用市售品,也可以使用通过化学合成而得到者。
<油脂>
本实施方式的表达增强剂可以还含有油脂。此时,表达增强剂变得更适合用于经口给予。
<油脂的种类>
本实施方式的表达增强剂中可以含有的油脂可以是动物油,也可以是植物油。作为油脂,例如可列举出玉米油、大豆油、芝麻油、菜籽油、红花油、橄榄油、蓖麻油、棉籽油、米油、葵花油、葡萄籽油和小麦胚芽油等植物油和蛋黄油、鱼油、鲸油、肝油等动物油、或它们的精制油(色拉油)、及如MCT(中链脂肪酸甘油三酯)、甘油二酯那样实施化学或酶处理而得到的食用油等。油脂可以单独使用1种,也可以组合使用2种以上。
<油脂的含量>
油脂的含量以表达增强剂总量为基准计可以为0.1质量%以上或1质量%以上,或者10质量%以下或8质量%以下。
<添加剂>
本实施方式的表达增强剂可以进一步含有添加剂(不包括紫檀芪和油脂在内)。作为添加剂,例如可列举出赋形剂、结合剂、润滑剂、崩解剂、乳化剂、表面活性剂、基剂、助溶剂、悬浮剂。
<制剂形态>
本实施方式的表达增强剂可以是固体(例如,粉末)、液体(水溶性或脂溶性的溶液或悬浮液)、糊剂等任意的形状。另外,可以是散剂、颗粒剂、片剂、胶囊剂、液体制剂、悬浮剂、糖浆剂等任意剂型。
<表达增强剂的制备方法>
上述的各种制剂可以通过将紫檀芪和根据需要使用的上述油脂和添加剂混合,并根据需要进行成型而制备。
关于微小RNA的表达增强剂的制备方法,以下对剂型为液体的情况进行说明。首先,准备已加热至材料温度50~90℃的油脂。向加热了的油脂中添加紫檀芪并使其溶解。然后,将紫檀芪和油脂的混合物与其它成分混合,根据需要进行灭菌处理等,能够制备含有紫檀芪的制剂。
<给予方法>
本实施方式的表达增强剂通过经口给予而能够发挥上述微小RNA的表达增强作用,因此能够用于经口给予用途。即,本实施方式的表达增强剂可以作为上述微小RNA中的1种或2种以上的经口给予用表达增强剂使用。通常,通过腹腔内给予等非经口给予而发挥期望效果的制剂即使经口给予也不一定发挥期望的效果。然而,本实施方式的表达增强剂不仅通过非经口给予可发挥微小RNA的表达增强效果,而且即使经口给予也可发挥微小RNA的表达增强效果。对于微小RNA的表达增强剂的给予量、给予时机、给予期,可以进行适宜设定。
<给予对象>
成为本实施方式的表达增强剂的给予对象的生物体优选为哺乳动物,更优选为人。
<给予量>
作为具体的给予量的一例,例如,对成人男子(体重60kg)进行给予时,每天的表达增强剂的给予量可以为0.01mg~5000mg/天/人,为0.05mg~1000mg/天/人、更优选为0.1mg~500mg/天/人、进一步优选为0.5mg~250mg/天/人。表达增强剂每天的给予量只要在上述范围内就可以进行1天1次给予,也可以1天分成多次(例如,2次或3次)进行给予。需要说明的是,给予量是以表达增强剂中的有效成分(即,紫檀芪)的量为基准的值。
<表达增强剂的用途>
本实施方式的表达增强剂可以用作药物、准药物、饮食品(饮料、食品)、饲料、饲料添加物等制品的成分。作为饮料,例如可列举出水、清凉饮料水、果汁饮料、乳饮料、酒精饮料、运动饮料、营养饮品等。作为食品,例如可列举出面包类、面类、米类、豆腐、乳制品、酱油、豆酱、点心类、奶油、酱汁类、蛋黄酱、调味汁等。另外,本实施方式的表达增强剂也可以用作健康食品、功能性标示食品、特殊用途食品、营养辅助食品、营养强化剂(例如,医用补充剂)或特定保健用食品等的成分。
<微小RNA表达增强用饮食品>
本实施方式的表达增强剂可以用作饮食品的成分。即,作为本发明的一实施方式,提供一种饮食品(食品组合物),其为包含紫檀芪的微小RNA表达增强用饮食品,微小RNA为选自由miR-200c、miR-141、miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
<增强微小RNA的表达的方法>
本发明的一实施方式也可以是增强微小RNA的表达的方法,其包括向需要其的对象给予紫檀芪的步骤。在该方法中,对于给予方法、给予对象、给予量等而言,可以与上述的表达增强剂中的情况同样。对象优选为哺乳动物,更优选为人。
<紫檀芪的用于制造表达增强剂的应用>
作为本发明的一实施方式,提供紫檀芪的用于制造微小RNA的表达增强剂的应用。需要说明的是,对于该实施方式中的给予方法、给予对象、给予量等而言,可以与上述的表达增强剂中的情况同样。
<用于增强微小RNA的表达的紫檀芪>
作为本发明的一实施方式,提供用于增强微小RNA的表达的紫檀芪。需要说明的是,对于该实施方式中的给予方法、给予对象、给予量等而言,可以与上述的表达增强剂中的情况同样。
实施例
以下,基于实施例等对本发明进行更具体地说明。但是,本发明不限定于以下的实施例。
(统计分析)
以下的实施例中,统计分析使用Kaleida Graph4.5(HULINKS公司),进行方差分析(One-Way ANOVA)后,通过多重比较(Tukey’s HSD Test)进行检验。
〔试验例1:微小RNA的表达量的评价〕
(粉末饲料用的试剂)
试验用的粉末饲料的制备中使用了以下的试剂。
酪蛋白(Oriental Yeast Co.,ltd.)
DL-甲硫氨酸(和光纯药工业株式会社)
β-玉米淀粉(Oriental Yeast Co.,ltd.)
蔗糖(KH1细白糖)(和田制糖株式会社)
纤维素粉末(Oriental Yeast Co.,ltd.)
玉米油(胚芽之惠玉米油)(J-OIL MILLS公司)
矿物质混合物(AIN-93G矿物质混合)(Oriental Yeast Co.,ltd.)
维生素混合物(AIN-93维生素混合)(Oriental Yeast Co.,ltd.)
酒石酸氢胆碱(和光纯药工业株式会社)(Lot.No.:PDQ0575、CTK0241)
90%紫檀芪(Silbinol)(Sabinsa Japan Corporation制)
(含有紫檀芪的粉末饲料的制备)
试验用的饲料(含有紫檀芪的粉末饲料)利用以下的方法制备。即,首先,称量50g玉米油,进行加热而使其达到70℃。在加热了的玉米油中添加紫檀芪并使其溶解。除玉米油和紫檀芪以外的试剂(其它试剂)用乳钵研磨进行混合。向其它试剂的混合物中添加溶解了紫檀芪的玉米油,用乳钵充分地研磨进行混合。然后,用搅拌机进一步混合约30分钟,制备了试验用的饲料。试验用的饲料中包含的各种成分的组成如表1所示。将试验用的饲料放入塑料袋中,在Koga Isotope,Ltd.进行γ射线灭菌后,用于后述的动物实验。另外,准备了表1所示的组成的驯化饲料(紫檀芪的含量:0质量%)。
[表1]
(实验动物)
作为实验动物,使用5周龄雌性的裸鼠(BALB/c-nu/nu,CAnN.Cg-Foxn1<nu>/CrlCjlj)(Charles River Laboratories公司)。
(试剂)
作为试剂,使用以下试剂。
ECM Gel from Engelbreth-Holm-Swam murine sarcoma(Invitrogen公司)
エスカイン(注册商标)吸入麻醉液(Pfizer公司)
甲虫荧光素(Beetle Luciferin),钾盐(Promega公司)
丙二醇(Sigma-Aldrich公司)
(饲养方法)
在保持在温度20~25℃、湿度40~60%的条件下的环境下饲养上述实验动物。作为喂食器,使用吊挂型的喂食器。
(试验组)
每组设为8只或10只,设定了(i)对照组(0%(w/w)紫檀芪组、n=18)和(ii)0.25%(w/w)紫檀芪组(n=18)这两组的试验区。
(试验方法和评价结果)
首先,让5周龄雌性的裸鼠在实验开始前适应环境1周左右。
作为含有紫檀芪的粉末饲料的经口给予对微小RNA的表达量的影响的研究,首先,用吊挂型喂食器给予对照饲料(驯化饲料)约1周后,分为(i)对照组和(ii)0.25%(w/w)紫檀芪组这两组。对照组中,经口给予了驯化饲料,紫檀芪组中,经口给予了含有紫檀芪的粉末饲料(紫檀芪的含量:0.25质量%)。
在分组起经过1周的时间点,对各组的小鼠进行了癌细胞移植实验。在癌细胞移植实验中,首先,将待移植的癌细胞(MM-231-luc-D3H2LN)悬浮于磷酸盐缓冲液(PBS),与基质胶(ECM Gel from Engelbreth-Holm-Swammurine sarcoma)以1:1的比率进行混合,准备了移植用的悬浮液(细胞数:1×105个细胞/ml)。接着,在异氟烷(エスカイン(注册商标)吸入麻醉液)麻醉下,将1×104个癌细胞移植(导入100μl上述的移植用的悬浮液(细胞数:1×105个细胞/ml))到小鼠的乳腺。通过如下方式进行癌细胞已移植的确认:在移植后静置一段时间,以150mg/kg的量向腹腔内给予15mg/ml荧光素溶液(Beetle Luciferin,PotassiumSalt、Promega公司),在约10分钟后用IVIS Spectrum(Perkin Elmer公司)测定细胞来源的发光(荧光素酶活性),从而进行。每天适宜地管理试验用的饲料和小鼠的状态。小鼠的体重进行适时测量。给予开始日(第0天)是移植癌细胞(肿瘤)当天。此外,从给予开始日起每隔一周通过IVIS spectrum经时观察发光。
在从给予开始经过21天的时间点,在异氟烷麻醉下摘出肿瘤,进行了安乐死。将各组(对照组或紫檀芪组)中摘出的肿瘤作为测定用的试样,利用以下所示的方法,进行了miR-200c、miR-141、miR-34a、miR-16、miR-126、miR-193b和let-7a的表达量的定量分析。需要说明的是,本试验例重复进行了两次独立试验。
首先,使用miRNeasy(注册商标)Mini Kit,依据制造商推荐的方案,从测定用的试样中提取了RNA。对于提取的RNA,使用TaqMan(注册商标)MicroRNA assay和TaqMan(注册商标)MicroRNA Reverse TranscriptionKit,分别依据制造商推荐的方案,转化为互补DNA(cDNA)。将该cDNA作为模板,使用TaqMan(注册商标)Universal PCR Master Mix,NoAmpErase(注册商标)UNG,通过StepOne PlusTM Real-Time PCR System(AppliedBiosystems)进行了miRNA的定量分析。将结果示于图1~2。图1~2中,误差条表示标准误差。
(评价结果)
如图1~2所示,经口给予了紫檀芪的组(紫檀芪组)与对照组相比,miR-200c、miR-141、miR-34a、miR-16、miR-126、miR-193b和let-7a的表达得到了增强。
序列表
<110> 丘比株式会社(Kewpie Corporation)
<120> 微小RNA的表达增强剂和微小RNA表达增强用饮食品
<130> FP19-1206-00
<150> JP2019-042523
<151> 2019-03-08
<160> 7
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> RNA
<213> 智人(Homo sapiens)
<400> 1
uaauacugcc ggguaaugau gga 23
<210> 2
<211> 22
<212> RNA
<213> 智人(Homo sapiens)
<400> 2
uaacacuguc ugguaaagau gg 22
<210> 3
<211> 22
<212> RNA
<213> 智人(Homo sapiens)
<400> 3
uggcaguguc uuagcugguu gu 22
<210> 4
<212> RNA
<213> 智人(Homo sapiens)
<400> 4
<210> 5
<211> 22
<212> RNA
<213> 智人(Homo sapiens)
<400> 5
ucguaccgug aguaauaaug cg 22
<210> 6
<211> 22
<212> RNA
<213> 智人(Homo sapiens)
<400> 6
aacuggcccu caaagucccg cu 22
<210> 7
<211> 22
<212> RNA
<213> 智人(Homo sapiens)
<400> 7
ugagguagua gguuguauag uu 22
Claims (10)
1.一种表达增强剂,其为含有紫檀芪的微小RNA的表达增强剂,
所述微小RNA为选自由miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
2.根据权利要求1所述的表达增强剂,其用于经口给予。
3.一种表达增强剂,其为含有紫檀芪的经口给予用的微小RNA的表达增强剂,
所述微小RNA为选自由miR-200c和miR-141组成的组中的至少1种。
4.一种饮食品,其为包含紫檀芪的微小RNA表达增强用饮食品,
所述微小RNA为选自由miR-200c、miR-141、miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
5.一种增强微小RNA的表达的方法,其包括向需要其的对象给予紫檀芪的步骤,
所述微小RNA为选自由miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
6.一种增强微小RNA的表达的方法,其包括向需要其的对象经口给予紫檀芪的步骤,
所述微小RNA为选自由miR-200c和miR-141组成的组中的至少1种。
7.一种紫檀芪的应用,用于制造微小RNA的表达增强剂,其中,
所述微小RNA为选自由miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
8.一种紫檀芪的应用,用于制造经口给予用的微小RNA的表达增强剂,其中,
所述微小RNA为选自由miR-200c和miR-141组成的组中的至少1种。
9.一种紫檀芪,其用于增强微小RNA的表达,
所述微小RNA为选自由miR-34a、miR-16、miR-126、miR-193b和let-7a组成的组中的至少1种。
10.一种紫檀芪,其用于通过经口给予而增强微小RNA的表达,所述微小RNA为选自由miR-200c和miR-141组成的组中的至少1种。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019042523A JP6830976B2 (ja) | 2019-03-08 | 2019-03-08 | マイクロrnaの発現亢進剤及びマイクロrna発現亢進用飲食品 |
JP2019-042523 | 2019-03-08 | ||
PCT/JP2020/009481 WO2020184390A1 (ja) | 2019-03-08 | 2020-03-05 | マイクロrnaの発現亢進剤及びマイクロrna発現亢進用飲食品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113543847A true CN113543847A (zh) | 2021-10-22 |
Family
ID=72355444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080018663.XA Pending CN113543847A (zh) | 2019-03-08 | 2020-03-05 | 微小rna的表达增强剂和微小rna表达增强用饮食品 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220170014A1 (zh) |
JP (1) | JP6830976B2 (zh) |
CN (1) | CN113543847A (zh) |
WO (1) | WO2020184390A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023182507A1 (ja) * | 2022-03-24 | 2023-09-28 | 北海道公立大学法人 札幌医科大学 | 薬学的組成物、間葉系幹細胞の三次元培養物の製造方法、エクソソームの製造方法、および薬学的組成物の製造方法 |
CN117398404B (zh) * | 2023-12-15 | 2024-03-08 | 北京大学口腔医学院 | 一种miRNA-141-5p在制备用于治疗牙周炎症性疾病药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013051459A1 (ja) * | 2011-10-02 | 2013-04-11 | キユーピー 株式会社 | RNA干渉によるmRNA発現の抑制を促進する促進剤およびその用途 |
US20160324801A1 (en) * | 2015-07-08 | 2016-11-10 | Therapeutic Solutions International, Inc. | Augmentation of oncology immunotherapies by pterostilbene containing compositions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6573740B2 (ja) * | 2017-09-08 | 2019-09-11 | キユーピー株式会社 | 抗腫瘍剤、癌予防用飲食品及び癌抑制的マイクロrnaの発現亢進剤 |
-
2019
- 2019-03-08 JP JP2019042523A patent/JP6830976B2/ja active Active
-
2020
- 2020-03-05 WO PCT/JP2020/009481 patent/WO2020184390A1/ja active Application Filing
- 2020-03-05 CN CN202080018663.XA patent/CN113543847A/zh active Pending
- 2020-03-05 US US17/436,721 patent/US20220170014A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013051459A1 (ja) * | 2011-10-02 | 2013-04-11 | キユーピー 株式会社 | RNA干渉によるmRNA発現の抑制を促進する促進剤およびその用途 |
US20160324801A1 (en) * | 2015-07-08 | 2016-11-10 | Therapeutic Solutions International, Inc. | Augmentation of oncology immunotherapies by pterostilbene containing compositions |
Non-Patent Citations (2)
Title |
---|
MCCORMACK, DENISE ELIZABETH等: "Genomic Analysis of Pterostilbene Predicts Its Antiproliferative Effects Against Pancreatic Cancer In Vitro and In Vivo", 《JOURNAL OF GASTROINTESTINAL SURGERY》, vol. 16, no. 6, XP035057855, DOI: 10.1007/s11605-012-1869-7 * |
WAKIMOTO, REI等: "Differential Anticancer Activity of Pterostilbene Against Three Subtypes of Human Breast Cancer Cells", 《ANTICANCER RESEARCH》, vol. 37, no. 11, XP055738597, DOI: 10.21873/anticanres.12064 * |
Also Published As
Publication number | Publication date |
---|---|
JP6830976B2 (ja) | 2021-02-17 |
WO2020184390A1 (ja) | 2020-09-17 |
US20220170014A1 (en) | 2022-06-02 |
JP2020143030A (ja) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9492424B2 (en) | Muscle atrophy inhibitor | |
CN113543847A (zh) | 微小rna的表达增强剂和微小rna表达增强用饮食品 | |
KR20040095263A (ko) | 체온상승제 | |
JP2018172302A (ja) | チュアブルタブレット | |
JP6613387B2 (ja) | 抗腫瘍剤、癌予防用飲食品及び癌抑制的マイクロrnaの発現亢進剤 | |
WO2004075905A1 (ja) | 筋肉増強剤および筋肉減衰の予防または治療剤 | |
JP5175442B2 (ja) | ヤーコン由来の抗ガン剤 | |
US11191285B2 (en) | Allulose-containing composition for promoting excretion of vegetable lipids from the body | |
JP5922862B2 (ja) | ミトコンドリア機能向上剤 | |
JP7411563B2 (ja) | クラスiのグルコーストランスポーター(glut)の発現誘導剤、並びにこれを用いた医薬組成物および飲食品組成物 | |
AU2013367872B2 (en) | Igf-1 production-promoting agent | |
JP5702292B2 (ja) | パーキンソン病患者の内臓脂肪減少抑制剤 | |
JPWO2020085155A1 (ja) | 還元型コエンザイムq10を含む経口用組成物、その製造方法、変色抑制方法及び変色抑制剤 | |
TWI834743B (zh) | 含還原型輔酶q10之經口用組成物、其製造方法、變色抑制方法及變色抑制劑 | |
JP6903367B1 (ja) | 抗肥満用組成物及び経口用組成物 | |
JP2005247754A (ja) | 抗腫瘍剤 | |
WO2022043287A1 (en) | Adonirubin and dha to prevent chronic inflammation | |
CN114222572A (zh) | 微小rna的表达调节剂 | |
JP2022000011A (ja) | 抗肥満用組成物及び経口用組成物 | |
KR20160010027A (ko) | 가르시아캄보지아(hca)를 유효성분으로 함유하는 체지방 감소를 위한 조성물 | |
JP2013091616A (ja) | 上皮型ナトリウムチャネル発現抑制剤 | |
JPWO2003074042A1 (ja) | 脱共役蛋白質発現亢進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |